These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Kaposi's sarcoma: DaunoXome approved.
    Journal: AIDS Treat News; 1996 May 03; (no 246):3-4. PubMed ID: 11363485.
    Abstract:
    The Food and Drug Administration (FDA) approved DaunoXome, a liposomal form of the cancer chemotherapy drug daunorubicin, for the treatment of patients with advanced HIV-related Kaposi's Sarcoma (KS). Not recommended for less than advanced KS, DaunoXome's primary advantage is fewer side effects than conventional chemotherapy. Liposomal drugs tend to target both KS lesions and cancer tumors. Although it is not known why, it is suspected that the liposomes leak out of defective blood vessels which grow in the lesions or tumors. The major toxicity of DaunoXome is bone-marrow suppression. Because the conventional form of daunorubicin presents a long-term risk of cumulative heart toxicity, the DaunoXome package insert includes a warning to monitor for possible heart toxicity. Treatment may need to be continued indefinitely since chemotherapy is not a cure for KS. DaunoXome, marketed by NeXstar Pharmaceuticals of San Dimas, CA, is the second approved liposomal chemotherapy drug. DOXIL (liposomal doxorubicin) was approved first in late 1995. Priced less than DOXIL, DaunoXome is infused once every 3 weeks. NeXstar offers a patient-assistance program to help with treatment costs.
    [Abstract] [Full Text] [Related] [New Search]